Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Inspire Medical Systems ( (INSP) ) has issued an announcement.
On January 12, 2026, Inspire Medical Systems reported preliminary, unaudited revenue for the fourth quarter and full year 2025, indicating continued double‑digit growth and strong adoption of its fifth‑generation Inspire V system. Fourth-quarter 2025 revenue is expected to come in at approximately $268.9 million to $269.1 million, up about 12% from a year earlier, while full‑year 2025 revenue is anticipated in the range of $911.8 million to $912.0 million, representing roughly 14% growth over 2024. The company also issued initial 2026 guidance, projecting revenue between $1.003 billion and $1.013 billion, or 10% to 11% growth, and noted that this outlook does not yet factor in any potential upside from recent reimbursement developments, which remain subject to coding clarification. In a parallel leadership move, the board on January 9, 2026 approved the appointment of veteran finance executive Matt Osberg as Executive Vice President and Chief Financial Officer, effective after filing the 2025 Form 10‑K, with a compensation package that includes salary, bonus eligibility, equity incentives and change‑of‑control protections, while current CFO Richard Buchholz will serve as interim CFO through the completion of the 2025 annual report, underscoring a managed transition in the company’s financial leadership as it enters its next phase of growth.
The most recent analyst rating on (INSP) stock is a Buy with a $120.00 price target. To see the full list of analyst forecasts on Inspire Medical Systems stock, see the INSP Stock Forecast page.
Spark’s Take on INSP Stock
According to Spark, TipRanks’ AI Analyst, INSP is a Outperform.
Inspire Medical Systems shows strong financial performance and positive corporate events, contributing to a solid overall score. However, technical indicators suggest a bearish trend, and the high P/E ratio indicates potential overvaluation, which tempers the overall score.
To see Spark’s full report on INSP stock, click here.
More about Inspire Medical Systems
Inspire Medical Systems, Inc., listed on the NYSE under the ticker INSP, is a medical technology company specializing in innovative, minimally invasive therapies for patients with obstructive sleep apnea. Its flagship Inspire therapy is a proprietary neurostimulation system and is the first of its kind to receive approvals from the FDA, EU MDR and Japan’s PDMA for the treatment of moderate to severe obstructive sleep apnea, positioning the company in a high-growth niche of the sleep-disorder treatment market.
Average Trading Volume: 1,543,698
Technical Sentiment Signal: Sell
Current Market Cap: $2.76B
Find detailed analytics on INSP stock on TipRanks’ Stock Analysis page.